Skip to main content
Premium Trial:

Request an Annual Quote

Orion Genomics Licenses IP from Johns Hopkins for Early Colorectal Cancer Test

This article has been updated from an earlier version to clarify the fact that the proposed test would be for prognostic, not diagnostic, use.
 
NEW YORK (GenomeWeb News) – Orion Genomics has licensed exclusive, worldwide rights from the Johns Hopkins University to a gene that it plans to use in a test for early prognosis of colorectal cancer.
 
Under the agreement, Orion has licensed the rights to use JHU technology related to the insulin-like growth factor 2 gene to develop a blood-based risk assessment test for people who may have an increased risk for developing sporadic colorectal cancer. The company expects that the test will make it possible for patients considered to be at risk for colorectal cancer to be tested “significantly earlier,” which could allow doctors to remove precancerous polyps to prevent the onset of colon cancer.
 
Orion said that research has shown that colorectal cancer and adenoma patients are more likely to carry the IGF2 biomarker than cancer-free control groups.
 
Orion Genomics CEO Nathan Lakey said that the test has the potential to test people “who should undergo colonoscopy screening 10 to 20 years earlier than the age that is currently recommended.” The American Cancer Society currently recommends that both men and women should begin getting screens for the disease at age 50.
 
Johns Hopkins University researchers currently are involved in a multi-center trial to study the link between IGF2 and colorectal cancer.
 
“The test may identify people who should be screened earlier in life and more frequently, while also identifying individuals who can start screening later than what is now recommended, thus serving as a tool to help physicians in developing targeted monitoring plans and shifting resources to the people most likely to develop colon cancer,” said Graham Colditz, associate director of prevention and control at the Alvin J. Siteman Cancer Center.
 
Further terms of the agreement were not released.
 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.